Nicotinamide riboside fails to improve Parkinson outcomes in NOPARK trial

Nicotinamide riboside did not improve clinical outcomes in people with early Parkinson disease in a randomized trial published October 8 in JAMA. The primary comparison favored placebo, delivering a consequential negative result for a compound investigated for its ability to increase nicotinamide adenine dinucleotide, or NAD.

The NOPARK findings matter to healthspan research because they test whether a promising metabolic intervention produces measurable clinical benefit. They do not establish effects on human lifespan or aging generally, but they weaken the case for using nicotinamide riboside to modify early Parkinson disease.

What the trial found

Researchers randomized 410 participants at 11 Norwegian centers to nicotinamide riboside or placebo for 52 weeks. The phase 3 study was double-blind, and 393 participants entered the primary analysis. Participants had been diagnosed within two years and were receiving stable dopaminergic treatment before enrollment.

The primary endpoint measured change in the combined parts I–III of the Movement Disorder Society Unified Parkinson Disease Rating Scale. Higher scores indicate worse disease. The adjusted difference was 2.72 points in favor of placebo, with a 95% confidence interval of 0.47 to 4.98 points.

Four of five key secondary outcomes showed no significant difference. Nonmotor symptom burden worsened more with nicotinamide riboside. Serious adverse events occurred in 8.3% of the active-treatment safety group and 14.1% of the placebo group; that numerical difference does not establish a safety benefit.

Statistical significance needs clinical context

The University of Bergen’s October 9 account emphasized that the primary difference was modest and below the usual threshold for clinically relevant worsening in an individual patient. That qualification helps prevent the statistically significant result from being interpreted as a large deterioration for every participant.

The university also reported that brain imaging did not indicate that treatment either slowed or accelerated disease progression. Together, these findings support a clear conclusion about the absence of demonstrated benefit, while requiring care about claims that the compound accelerated the underlying neurodegenerative process.

The trial was supported by Norwegian research and health funding organizations. ChromaDex, a Niagen Bioscience company, supplied the study compound and placebo, according to the institutional release.

Why earlier findings were insufficient

The biological rationale had support from a much smaller study. NADPARK, published in Cell Metabolism in 2022, randomized 30 newly diagnosed, treatment-naive patients to nicotinamide riboside or placebo for 30 days.

That phase 1 study found a variable increase in brain NAD levels. Participants whose brain NAD increased also showed changes in cerebral metabolism associated with mild clinical improvement. The authors described those findings as grounds for larger trials.

A short study showing metabolic activity answers a different question from a year-long clinical trial. Its small population and brief observation period could not establish sustained disease modification. NOPARK supplied the larger clinical test that the earlier findings warranted.

What remains unanswered

NOPARK evaluated one compound in a defined disease population over one year. Its findings cannot automatically be transferred to other NAD precursors, people without Parkinson disease, or different clinical indications.

For longevity research, the practical implication is that evidence of biological activity needs confirmation through outcomes that matter to patients. Future studies proposing benefits from NAD interventions will need their own clinical evidence; the earlier metabolic signals cannot substitute for the benefit NOPARK failed to demonstrate.